Welcome to our dedicated page for Yarrow Bioscience SEC filings (Ticker: VYNE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Yarrow Bioscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Yarrow Bioscience's regulatory disclosures and financial reporting.
Yarrow Bioscience, Inc. reports initial holdings for director Peter B. Silverman. He holds a stock option to purchase 87,820 shares of common stock at an exercise price of $6.19 per share, expiring April 17, 2036. The option was received in a merger and one quarter vests on April 17, 2027, with the remainder vesting monthly over the following three years.
Sven Ante Lundberg, a director of Yarrow Bioscience, Inc., filed an initial beneficial ownership report showing a stock option covering 175,639 shares of common stock at an exercise price of $6.19 per share, expiring on April 17, 2036.
The option was received in connection with a merger involving VYNE Therapeutics Inc. and Yarrow Bioscience, Inc. and was assumed on the same terms, with one quarter vesting on April 17, 2027 and the remaining three quarters vesting in equal monthly installments over the following three years, subject to continued service.
Yarrow Bioscience, Inc., formerly VYNE Therapeutics Inc., reports that director Steven L. Hoerter holds a stock option to buy 87,820 shares of Issuer Common Stock at an exercise price of $6.19 per share, expiring on April 17, 2036.
The option was assumed in a merger effective July 27, 2026, converting prior Yarrow options into options on Issuer Common Stock on the same terms. One quarter of this option vests on April 17, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to Hoerter’s continued service.
Yarrow Bioscience, Inc. reports that Chief Operating Officer Rachael Alford holds a stock option to purchase 175,639 shares of its common stock at an exercise price of $6.1900 per share, expiring on January 30, 2036. The option was received in the merger in which a wholly owned subsidiary of VYNE Therapeutics Inc. merged with Yarrow Bioscience, after which VYNE changed its name to Yarrow Bioscience, Inc. One quarter of this option will vest on January 26, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to her continued service.
Lori Payton, Chief Development Officer of Yarrow Bioscience, Inc., reports holding a stock option covering 175639.0000 shares of Issuer Common Stock. The option carries a $6.1900 exercise price and expires on 2036-01-30, held as a direct derivative position.
These options were received in a merger in which a wholly owned subsidiary of VYNE Therapeutics Inc. merged into Yarrow Bioscience, after which VYNE changed its name to Yarrow Bioscience, Inc. One quarter of this option is scheduled to vest on 2027-01-02, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to Payton’s continued service.
Yarrow Bioscience, Inc. reports initial beneficial ownership for Chief Medical Officer Steven Ryder. He holds a stock option to purchase 228,330 shares of Issuer Common Stock at an exercise price of $6.19 per share, expiring on 2036-04-17.
The option was received in connection with the merger in which a wholly owned subsidiary of VYNE Therapeutics Inc. merged with Yarrow and VYNE changed its name to Yarrow Bioscience, Inc. One quarter of the option will vest on April 8, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to continued service.
Yarrow Bioscience, Inc., formerly VYNE Therapeutics Inc., reports Chief Executive Officer Rebecca Frey’s initial beneficial ownership consisting of a stock option to purchase 878,194 shares of common stock at an exercise price of $6.1900 per share, expiring on 2036-01-30, received in connection with a merger and subject to a multi‑year vesting schedule.
Perceptive Life Sciences Master Fund Ltd, Perceptive Advisors LLC and Joseph Edelman, each reported as a 10% owner of Yarrow Bioscience, Inc., disclose initial indirect holdings of 967,360 shares of Common Stock via immediately exercisable, non-expiring Pre-Funded Warrants at an exercise price of $0.0001 per share and 266,309 shares of Common Stock.
The warrants are subject to a 9.99% Beneficial Ownership Limitation that currently prevents any exercise, and Perceptive Advisors and Mr. Edelman disclaim beneficial ownership except for their indirect pecuniary interest in the Master Fund.
Yarrow Bioscience, Inc. received an Amendment No. 1 to a Schedule 13D from AI Biotechnology LLC, Access Industries Holdings LLC, Access Industries Management, LLC and Len Blavatnik, updating their beneficial ownership following a merger and 1-for-50 reverse stock split.
The reporting group now reports beneficial ownership of 178,180 shares of common stock, consisting of 22,331 shares held directly by AI Biotechnology and 155,849 shares issuable upon exercise of pre-funded warrants, representing 6.02% of Yarrow's common stock. The percentage is based on 2,803,078 shares outstanding after the merger plus the warrant shares. Before the reverse split, AI Biotechnology held 1,116,585 shares and warrants for 7,792,448 shares, which were proportionately adjusted. Upstream Access entities and Mr. Blavatnik may be deemed to share voting and dispositive power over these securities but disclaim beneficial ownership, and they report no other transactions in the past 60 days beyond those described.
Yarrow Bioscience, Inc. (formerly VYNE Therapeutics) completed its merger with privately held Yarrow Bioscience, making Yarrow a wholly owned subsidiary, changing its name and ticker to YARW, and effecting a 1-for-50 reverse stock split.
Based on valuations of $272.9 million for Pre-Merger Yarrow and $8.5 million for VYNE, each Yarrow share converted into 0.7171 shares of the public company. Immediately after closing, former Yarrow holders owned about 97% of the combined company and legacy VYNE holders about 3%, with roughly 2.8 million common shares outstanding, or 28.6 million on a fully diluted basis including pre-funded warrants.
Pre-Merger Yarrow raised $100 million in Series A preferred stock and $100 million in a PIPE that included 13,068,176 pre-funded warrants at a $0.0001 exercise price; the company expects this $200 million of financing to fund operations into 2028. Ahead of closing, VYNE paid a special cash dividend of $17.3 million, or $0.40242 per share. The combined company is led by a new Yarrow-dominated board and management team and is advancing lead antibody YB-101, which has FDA Fast Track for Graves’ disease, into an ongoing Phase 2a/2b trial.